baber/WOPTO huggingface dataset:
Patent NZ-568553-A (NZ)
Title: Treatment of inflammation, AB-induced cell toxicity, neuronal cell death or neuronal loss in subjects suffering from AlzheimerÆs disease
Inventor: GERVAIS FRANCINE
IPC: A61K31/381
Filed: 1999-02-11
Abstract: Disclosed is the use of an anionic compound, or a pharmaceutically acceptable salt thereof for the manufacture of a composition for the treatment or prevention of inflammation due to activation of macrophages by an amyloidogenic protein or peptide (such as soluble Amyloid-beta), or a functional fragment thereof; wherein said anionic compound has the structure: Q-[-Y-X+]n, where in Y is an anionic group at physiological pH (such as SO3); Q is a C3 aliphatic group; X+ is a cationic group; and n is an integer selected such that the biodistribution of the compound for an intended target site is not prevented while maintaining activity of said compound; with the proviso that said anionic compound is not 3-amino-1-propanesulfonic acid. Also disclosed is the above use, where the anionic compound is selected from the group consisting of 3-(cyclohexylamino)-1-propane sulfonate, 3-(N-morpholino)propanesulfonic acid.
Patent NZ-569753-A (NZ)
Title: A stream-driven vehicle for producing electrical energy from a water stream
Inventor: LANDBERG MAGNUS
IPC: F03B17/00
Filed: 2007-01-31
Abstract: Disclosed is a submersible plant for producing electrical energy from a water stream. The plant includes a turbine arrangement secured in a structure by means of a wire. The turbine arrangement is mounted to a stream-driven vehicle that is formed by at least one wing. The stream-driven vehicle can move freely within a range of the wire. The vehicle includes steering means and a control unit. The control unit is arranged to provide control signals to the steering means for steering the vehicle in a trajectory which at least partly crosses the direction of the water stream. The vehicle is capable of, when steered in the trajectory, being driven by the water stream with a velocity which is many times higher than the streaming velocity of the water.
Patent NZ-574888-A (NZ)
Title: IMIDAZOL[4,5-b]PYRAZINE DERIVATIVES AND USES THEREOF
Inventor: MUCI ALEX
IPC: A61K31/498
Filed: 2007-08-01
Abstract: Disclosed are imidazo[4,5-b]pyrazine derivatives represented by general formulae (I) and (II), or pharmaceutically acceptable salts thereof, wherein R1 is alkenyl or alkynyl, R4 is hydrogen and R2 is 3-pentyl, 4-heptyl, 4-methyl-1-morpholinopentan-2-yl, isobutyl, cyclohexyl, cyclopropyl, sec-butyl, tert-butyl, isopropyl, 1-hydroxybutan-2-yl, tetrahydro-2H-pyran-4-yl, 1-methoxybutan-2-yl, 1-aminobutan-2-yl, or1-morpholinobutan-2-yl. Also disclosed is the use of the compounds of formula (I) or (II) for treating neuromuscular disease.
Patent NZ-575500-A (NZ)
Title: Transdermal therapeutic system for administering the active substance buprenorphine
Inventor: HILLE THOMAS
IPC: A61K31/485
Filed: 2007-11-07
Abstract: Disclosed is a transdermal therapeutic system comprising: an active ingredient- impermeable backing layer, at least one pressure-sensitive adhesive matrix layer comprising the active ingredient buprenorphine and at least one carboxylic acid, and, if desired, a protective layer to be detached before use, characterized in that the matrix layer is constructed on the basis of polysiloxanes or polyisobutylene, the buprenorphine is in solution in the carboxylic acid or carboxylic acids, and the solution is in dispersion in the form of droplets in the matrix layer, the matrix layer is in diffusible contact with a self-adhesive skin contact layer based on polyacrylates, and the carboxylic acid diffuses into the skin more quickly than does the active ingredient buprenorphine.
Patent NZ-576739-A (NZ)
Title: Peptide vectors for delivering paclitaxel
Inventor: DONG ZHENG XIN
IPC: A61K47/48
Filed: 2004-04-21
Abstract: A compound according to the formula "X-B1-B2-B3-B4-Z" wherein: X is paclitaxel or a paclitaxel derivative, B1, B2, B3, and B4 are independently for each occurrence: (Doc)m, (Aepa)n, -(C(O)-A1-A2-A3-A4-A5-C(O))s-, or (amino acid)p; wherein the amino acid is selected from the group consisting of Gly, Val, Abu, Gaba, Doc, and Sar; A1 and A5 are, independently for each occurrence, CR1R2; wherein R1 and R2 are independently for each occurrence, H; A2, A3, and A4 are independently for each occurrence, CR6R7, (CH2)t or absent; wherein each of R6 and R7 is, independently for each occurrence, H; m is, independently for each occurrence, 0, 1, 2, 3, 4, 5, or 6; n is, independently for each occurrence, 0, 1, or 2; p is, independently for each occurrence, 0, 1, or 2; s is, independently for each occurrence, 1, 2, or 3; t is, independently for each occurrence, 0, 1, 2, or 3; and Z is a somatostatin, luteinizing hormone releasing hormone (LHRH) or bombesin peptide. Provided that: when X is paclitaxel or a paclitaxel derivative, then B1 is (amino acid)p, wherein the amino acid is selected from the group consisting of Sar, Gly, Val, Doc, and Gaba, and p is 1 or 2; and when X is paclitaxel or a paclitaxel derivative, at least one of B1, B2, B3 and B4 is (Doc)m and m is not 0; or a pharmaceutically acceptable salt thereof. The compounds are used to deliver the cytotoxic drug paclitaxel to cells expressing receptors for the peptides to treat diseases selected from fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis, breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, small cell lung cancer, ovarian cancer, epidermal cancer and haematopoietic cancer. (62) Divided Out of 564694
Patent NZ-582925-A (NZ)
Title: Use of bubropion hydrobromide for the prevention of seizures associated with bupropion administration
Inventor: WILLIAMS ROBERT PARRY
IPC: A61K9/28
Filed: 2008-08-06
Abstract: Disclosed is the use of bupropion hydrobromide in the production of a medicament for the prevention and/or reduction of convulsions and/or seizures associated with bupropion administration, wherein the bupropion administration is for the treatment or prevention of major depressive disorder, bipolar depression mood disorder, other mood disorder, anxiety disorders, generalised anxiety disorder, panic disorder, post-traumatic stress disorder, nicotine addiction, obesity, attention-deficit hyperactivity disorder, restless legs syndrome, sexual dysfunction or Parkinson's disease.
Patent NZ-583680-A (NZ)
Title: Enhanced method for monitoring the deposition of organic materials in a papermaking process
Inventor: SHEVCHENKO SERGEY M
IPC: D21G9/00
Filed: 2008-08-22
Abstract: Disclosed is a method for monitoring the deposition of one or more organic materials dispersed in an aqueous medium in a papermaking process comprising: measuring the rate of deposition of the organic materials from the aqueous medium on-to a quartz crystal microbalance having a top side contacting with the aqueous medium coated with a layer containing a cured non-swelling epoxy resin or a silicon containing polymer, and a second, bottom side isolated from the aqueous medium. Also disclosed is a method for measuring the effectiveness of inhibitors that decrease the deposition of one or more organic materials in a papermaking process comprising: a. monitoring one or more organic materials dispersed in an aqueous medium in a papermaking process comprising measuring the rate of deposition of the organic materials from the aqueous medium onto a quartz crystal microbalance having a top side contacting the aqueous medium coated with a layer containing a nonswelling epoxy resin or a silicon containing polymer, and a second, bottom side isolated from the aqueous medium; b. adding an inhibitor that decreases the deposition of the organic materials from the aqueous medium; and c. re-measuring the rate of deposition of the organic materials from the aqueous medium onto the coated surface of the quartz crystal microbalance.
Patent NZ-586677-A (NZ)
Title: Production of protein-polysaccharide conjugates
Inventor: LUCEY JOHN A
IPC: A23L29/20
Filed: 2009-03-19
Abstract: Disclosed is a method of preparing a polysaccharide-protein conjugate, comprising reacting a polysaccharide comprising a reducing sugar and a protein in an aqueous solution comprising 10-40% (w/v) polysaccharide and 1-30% (w/v) protein, under temperature conditions of from about 40°C to about 120°C, thereby producing a polysaccharide-protein conjugate.
Patent NZ-591995-A (NZ)
Title: Drive mechanism and a wheelbarrow incorporating it
Inventor: PORTER TIMOTHY
IPC: B62B1/00
Filed: 2011-03-29
Abstract: 591995 Disclosed is a motorised drive mechanism for a wheelbarrow to reduce operator effort. The drive mechanism includes a prime mover, mounting means for mounting the prime mover to a wheelbarrow, a hub that has attachment means for connecting the hub to the wheel of the wheelbarrow the attachment means being formed by at least one projection or finger that engages with a spoke or abutment of the wheel and a drive connector for connecting a drive from the prime mover to the hub. The prime mover is a petrol engine. The drive mechanism includes a remote means for controlling the drive from the prime mover to the hub, the remote means being adapted for mounting at or adjacent a handle of the wheelbarrow.
Patent NZ-592051-A (NZ)
Title: Ground column machine with inner screw and outer tubular screw with primarily vertical compaction
Inventor: MCMILLAN JARON LYELL
IPC: E02D3/00
Filed: 2012-03-19
Abstract: A drill assembly is disclosed for forming in ground granular columns without the need for vibratory compaction, said drill assembly includes a first drill and a second drill, where the first drill is a tube, and the second drill includes a drill flight, wherein said first and second drills are concentric, and the second drill is configured to lie at least partially within the first drill; such that the drill assembly is configured to form the granular column with primarily vertical compaction.
Patent NZ-595082-A (NZ)
Title: Benzothiadiazepine derivatives used as ampa and nmda receptor modulators
Inventor: DANOBER LAURENCE
IPC: A61K31/554
Filed: 2010-03-18
Abstract: IP No. 595082 The present disclosure relates to new benzothiadiazepine compounds of formula (I), to a process for their preparation, to pharmaceutical compositions containing them, and also to the use thereof as positive allosteric modulators of AMPA receptors and antagonists of NMDA receptors. Preferred compounds include: 8-phenoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide; ethyl 3-[(1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy]-benzoate; 3-[(1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy]-N-methyl benzamide; { 3-[(1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy]phenyl} -methanol; 4-[(1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy]phenol; 4-[(5-methyl-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy]phenol And; 4-[(1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy]aniline. Processes for their preparation are also disclosed along with the use of 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-ol 1,1-dioxide (compound of formula VI) as an intermediate. Conditions which the compounds of the disclosure may be used in the treatment or prevention of include: progressive neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Pick's disease, Huntington's chorea, Korsakoff's disease, schizophrenia, acute neurodegenerative diseases, frontal lobe and subcortical dementias, vascular dementias, epilepsy, cerebral vascular accidents and also depressive and anxious states.
Patent NZ-610039-A (NZ)
Title: Device for disinfecting and/or rinsing endoscopes with limited escape of fumes
Inventor: MINER NORMAN
IPC: A61B1/12
Filed: 2011-09-30
Abstract: Disclosed is an apparatus (10) and for disinfecting and/or rinsing an endoscope (34) and a device for disinfecting at least one endoscope (34). Automated machines for disinfecting and/or rinsing an endoscope are expensive and they are limited to disinfecting and rinsing at most two flexible endoscopes at the same time. Manual methods of disinfecting and/or rinsing endoscopes can lead to the escape of fumes which can cause irritation and sensitisation to the skin of personnel. The apparatus (10) comprises a basin (14); a reservoir (22); a disinfectant supply conduit (26) and a gas conduit (30). The basin (14) includes a body (16) and a lid (18). The body (16) is configured to receive an endoscope (34) such that the endoscope (34) can be submersed in liquid with a headspace in the basin (14) above the liquid. The lid (18) is configured to be coupled to the basin (14) and provide an airtight seal between the lid (18) and body (16). The reservoir (22) includes a top and is configured to receive a liquid with a headspace between the liquid and top. The disinfectant supply conduit (26) is coupled to the basin (14) and to the reservoir (22) and it is configured to communicate liquid from the reservoir (22) to the basin (14). The gas conduit (30) is coupled to the basin (14) and to the reservoir (22). The gas conduit (30) is configured to communicate gas between the headspace of the basin (14) and the headspace of the reservoir (22).
Patent NZ-616730-A (NZ)
Title: System, method, and computer program product for creation, transmission, and tracking of electronic package
Inventor: ALLARDYCE MARK
IPC: G06Q10/10
Filed: 2012-03-15
Abstract: 616730 A system for creating and delivering a locked electronic document in a computing environment includes a computer readable system memory comprising at least one program module, a bus coupled to the computer readable system memory, a processor coupled to the bus, and program instructions stored on the system memory for execution by the processor. The program instructions create a lead sheet having a unique embedded identifier, add a payload to the lead sheet to form the electronic package, add a blanking layer to the electronic package to obscure the payload from view of a recipient, send the electronic package in the computing environment to a designated recipient, validate the designated recipient’s identity, and remove the blanking layer in response to validating the designated recipient’s identity, thereby allowing the recipient to view the payload.
Patent NZ-622327-A (NZ)
Title: Methods of identifying sleep & waking patterns and uses
Inventor: LOW PHILIP
IPC: A61B5/0476
Filed: 2009-11-16
Abstract: Disclosed is a method for determining a parameter from brainwave data. The method comprises the step of attaching at least a single non-invasive electrode to a non-human animal; (502) wirelessly obtaining data indicative of brainwave activity from the non-invasive electrode; (504) analysing the data indicative of brainwave activity; and determining at least one parameter indicative of a level of attentiveness or a level of alertness from the analysing. The step of analysing the data comprises conducting a first frequency normalisation over time and conducting a second frequency normalisation across frequencies for producing a doubly normalised spectrogram.
Patent NZ-624378-A (NZ)
Title: Fluid cooled lances for top submerged injection
Inventor: MATUSEWICZ ROBERT
IPC: F27D3/18
Filed: 2012-11-26
Abstract: A top submergible injection lance L operable for use in a top submerged lancing injection within a slag layer of a molten bath in a pyrometallurgical process, where the lance L has an outer shell S of three substantially concentric lance pipes P1, P2, P3 comprising an outermost, an innermost and an intermediate pipe. The lance L includes at least one further lance pipe P4 arranged substantially concentrically within the shell S. The shell S further includes an annular end wall W at an outlet end of the lance L which joins a respective end of the outermost and innermost lance pipes of the shell S at an outlet end of the lance L and is spaced from an outlet end of the intermediate lance pipe of the shell S. At a location remote from the outlet end, such as adjacent to an upper or inlet end, the lance L has a structure by which it is suspendable so as to hang down vertically. The shell S is adapted whereby coolant fluid is able to be circulated through the shell S, by flow between the intermediate lance pipe P2 and one of the innermost and outermost lance pipes to the outlet end and then back along the lance L, away from the outlet end, by flow between the intermediate lance pipe P2 and the other one of the innermost and outermost lance pipes. The spacing between the end wall and the outlet end of the intermediate pipe provides a constriction to the flow of coolant fluid which causes an increase in coolant fluid flow velocity between the end wall and the outlet end of the intermediate pipe. The further lance pipe P4 defines a central bore and has an outlet end spaced from the outlet end of the outer shell S. A mixing chamber M is defined by the outer shell S between the outlet ends of the outer shell S and of the at least one further pipe. The at least one further lance pipe is spaced from the innermost lance pipe of the shell S to define there between an annular passage, whereby combustible material passing along the bore and oxygen containing gas passing along the annular passage are able to form a combustible mixture in the mixing chamber and adjacent to the outlet end of the lance L for combustion of the mixture in being injected within the slag layer
Patent NZ-624972-A (NZ)
Title: Subcutaneous therapeutic use of dpp-4 inhibitor
Inventor: KLEIN THOMAS
IPC: A61P3/10
Filed: 2012-12-28
Abstract: Disclosed is the use of linagliptin and one of a GLP-1 analogue having a short half-life or native GLP-1, for the manufacture of a medicament, effective in the treatment of obesity or overweight or for reducing body weight in a subject in need thereof, wherein the medicament is administered subcutaneously.
Patent NZ-627586-A (NZ)
Title: Pyridone derivatives
Inventor: WATANABE HIDEAKI
IPC: C07D471/08
Filed: 2013-01-30
Abstract: The disclosure relates to pyridine derivatives of general formula (1). The disclosure also relates to crystal forms of these compounds. These compounds could be of use in the treatment of diseases caused by hyperfunction of Axl and diseases related to hyperfunction of Axl. Example compounds include: N-{ 4-[2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl} -5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroeythyl)-1,4-dihydropyridine-3-carboxamide N-[4-(4-Amino-6-methoxypyrimidin-5-yl)phenyl]-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide N-[4-(2-Amino-4-methoxypyridin-3-yl)-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide N-[4-(2-Amino-4-methoxypyridin-3-yl)phenyl]-5-(4-fluoropheny1)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide
Patent NZ-629459-A (NZ)
Title: Methods for treating cancer using tor kinase inhibitor combination therapy
Inventor: CHOPRA RAJESH
IPC: A61P35/02
Filed: 2014-04-16
Abstract: Disclosed herein is the use of an effective amount of an effective amount of a TOR kinase inhibitor represented by structural formula (I) and an effective amount of a 5-Substituted Quinazolinone Compound in the manufacture of a medicament for treating or preventing cancer, particularly a liver cancer or a blood borne cancer which includes a lymphoma, a leukemia or a mutliple myeloma, wherein the variables shown in formula (I) are as defined in the specification. The preferred TOR kinase inhibitor is 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one or 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
Patent NZ-631085-A (NZ)
Title: Infant formula milk powder and preparation method thereof
Inventor: SHAO SHENGRONG
IPC: A23L33/00
Filed: 2013-05-24
Abstract: Disclosed is an infant formula milk powder, comprising the following components: 5—20 parts by weight of vegetable oil, 187-427 parts of fresh milk, 20—35 parts by weight of whey powder, 12.23—21.753 parts by weight of lactose, 2-4 parts by weight of whey protein powder, 1 .5-2.5 parts by weight of oligosaccharides, 0.1 5-0.2 part by weight of vitamins, 0.35-0.6 part by weight of minerals, 1-1 .5 parts by weight of other nutrients in the infant formula milk powder, 0.02-0.1 part by weight of lactoferrin, and vitamin C, characterised in that the mass ratio of lactoferrin to vitamin C is 1:3 to 1:1. Further disclosed is an ¡nfant formula milk powder, comprising the following components 25—35 parts by weight of vegetable fat powder, 30—42.5 parts by weight of powdered milk, 21 .5—30 parts by weight of whey powder, 1 .096—8.93 parts by weight of solid glucose syrup, 2—4 parts by weight of whey protein powder, 1 .5—2.5 parts by weight of oligosaccharides, 0.15—0.2 part by weight of vitamins, 0.35—0.6 part by weight of minerals, 1—1.5 parts by weight of other nutrients in the infant formula milk powder, 0.02—0.1 part by weight of lactoferrin, and vitamin C, characterised in that the mass ratio of lactoferrin to vitamin C is 1:3 to 1:1.
Patent NZ-702694-A (NZ)
Title: Single use breathing mask with adhesive gasket
Inventor: DALY ROBERT W
IPC: A62B18/08
Filed: 2013-06-06
Abstract: The present invention relates to a breathing mask and a method of making a breathing mask for use in connection with a therapeutic breathing apparatus that allows improved adhesion to the patient’s face to facilitate improved sealing and performance. A need exists in the art for a mask with an adhesive based seal that effectively seals to a patient’s face without inducing undue stress points on the seal or the patient’s skin that can form a seal to a patient’s face while reducing complexity and the need for a variety of straps and harnesses. The present invention is a layered mask construction including a relatively hard attachment shell assembly and a flexible gasket. A first portion of the gasket is performed in a molding or heat press process such that the contours are created within the foam material itself prior to laminating the assembly with the shell. It is an important feature of the present invention that the surface area of the gasket layer be greater than the surface area of the interior of the inner shell. Preferably the surface area of the gasket is at least twice the surface area of the interior shell. More preferably the surface area of the gasket is three times the surface area of the interior shell. This allows a large area of adhesive having a lower adhesion to be employed in a manner that counteracts the uplift force of the therapy pressure.
Patent NZ-705813-A (NZ)
Title: Treatment of mild and moderate alzheimer’s disease
Inventor: VALCARCE LOPEZ MARIA CARMEN
IPC: A61P25/28
Filed: 2013-10-02
Abstract: The present invention relates to methods of treatment using [3-(4-{ 2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl amine (”COMPOUND I”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of Alzheimer’s type, diabetes, insomnia, and other indications. The present invention also relates to pharmaceutical compositions comprising COMPOUND I or a pharmaceutically acceptable salt thereof.
Patent NZ-708529-A (NZ)
Title: Salt and solvates of a tetrahydroisoquinoline derivative
Inventor: MCCARTHY THOMAS DAVID
IPC: C07D217/26
Filed: 2011-07-21
Abstract: Disclosed herein is the crystalline non-solvate sodium salt of the compound (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid and solvates thereof. Also disclosed are the free acid compound with a high chemical purity (above 96%) and/or a high enantiomeric excess (above 97%). The compound is also known as EMA401 and is an angiotension II type 2 receptor antagonists. AT2 receptor antagonists are useful in treating pain, inflammatory pain and neuropathic pain.